Welcome to our dedicated page for ZYNEX news (Ticker: ZYXI), a resource for investors and traders seeking the latest updates and insights on ZYNEX stock.
Zynex Inc (NASDAQ: ZYXI), founded in 1996, is a trailblazer in the medical technology sector. The company designs, manufactures, and markets non-invasive medical devices aimed at pain management, rehabilitation, and patient monitoring. Operating through its subsidiaries, Zynex Medical, Zynex Monitoring Solutions, and Zynex NeuroDiagnostics, the company has a diverse product portfolio and a strong commitment to improving the quality of life for its patients.
Zynex Medical leads the charge in developing electrotherapy devices for home use, aiding in the treatment of chronic and acute pain while also facilitating muscle activation and rehabilitation. Their product lineup includes the likes of NexWave, NeuroMove, InWave, and E-Wave, all of which are FDA/CE cleared and commercially available.
Zynex Monitoring Solutions focuses on cardiac monitoring devices used in hospital settings. Although still in development, these products aim to revolutionize patient care by providing advanced monitoring solutions that are non-invasive and highly effective.
Zynex NeuroDiagnostics specializes in the development of devices for electromyography (EMG) and electroencephalography (EEG) applications within neurology. These cutting-edge diagnostic tools are designed to assist healthcare professionals in diagnosing and treating neurological conditions.
The company has made significant strides in recent years. In 2024, Zynex was recognized as the 9th among the Top 25 Medical Device Companies by The Healthcare Technology Report. This recognition underscores the company's influence and innovation within the medical technology landscape.
In terms of financial performance, Zynex has shown robust growth. For the fiscal year 2023, the company reported net revenues of $184.3 million, reflecting a 17% increase from the previous year. This growth is attributed to a 43% increase in device orders, highlighting the expanding reach and effectiveness of Zynex's sales strategy.
In addition to financial success, Zynex has introduced new products aimed at diversifying its revenue streams. The Zynex Pro Hybrid LSO, a versatile 3-in-1 spinal orthosis, and the Zynex DynaComp Cold Compression, a device combining cold therapy and compression, are recent additions that have received positive market feedback.
Looking ahead, Zynex is poised for continued growth and innovation. The company anticipates a 23% increase in net revenue for 2024, driven by new product introductions and an expanding direct sales force. With a focus on non-invasive, holistic approaches to pain management and patient care, Zynex aims to set new standards in the medical technology industry.
Zynex, a medical technology company listed under Nasdaq: ZYXI, has announced it will report its first-quarter financial results for 2023 on April 27, 2023. The report will include insights into their non-invasive medical devices for pain management and rehabilitation. Management will discuss the results during a conference call and webcast scheduled for 2:15 PM MT / 4:15 PM ET. Interested participants can register via the provided link or dial in.
Founded in 1996, Zynex specializes in developing and selling medical devices used in hospitals and patient care. The company emphasizes its forward-looking statements regarding future conditions and the inherent uncertainties involved.
Zynex, Inc. (NASDAQ: ZYXI) reported preliminary results for Q1 2023, showcasing significant growth in the pain management division. Orders reached a record high, up 61% from Q1 2022. Revenue estimates for the quarter are projected between $39.0 million and $41.0 million, reflecting a 29% increase from the previous year. The company maintains its full-year guidance, forecasting revenue of $180 million to $200 million and earnings per share between $0.40 and $0.50. Seasonal trends in the healthcare industry affect Q1 revenues, aligning with historical patterns. CEO Thomas Sandgaard emphasized strong sales momentum and growth potential as the company expands its market presence.
Zynex, Inc. (NASDAQ: ZYXI) has been ranked 191 out of 500 on The Financial Times' fourth annual list of The Americas' Fastest Growing Companies 2023. This recognition highlights Zynex's consistent revenue growth, achieving a remarkable 308% increase in revenue and a compound annual growth rate (CAGR) of 60% between 2018 and 2021. CEO Thomas Sandgaard emphasized that this accolade reflects the company's ongoing performance along with 24 other publicly traded companies in the Healthcare & Life Sciences sector. Zynex specializes in non-invasive medical devices for pain management, rehabilitation, and patient monitoring.
Zynex, Inc. (Nasdaq: ZYXI) reported strong financial results for Q4 and full year 2022, highlighting a 21% revenue growth year-over-year to $48.8 million for Q4, with orders up 48%. Full year revenue also increased 21%, totaling $158.2 million, while net income reached $17.0 million, reflecting profitability for the seventh consecutive year. The company's working capital stood at $48.5 million, with cash on hand at $20.1 million. For 2023, Zynex projects revenue between $180 million and $200 million, anticipating first quarter revenue of $39-41 million, influenced by seasonal trends.
FAQ
What is the current stock price of ZYNEX (ZYXI)?
What is the market cap of ZYNEX (ZYXI)?
What does Zynex Inc specialize in?
What are the key products offered by Zynex Medical?
Is Zynex a publicly traded company?
What recent achievements has Zynex Inc made?
What are Zynex's future growth plans?
What subsidiaries does Zynex operate through?
What financial performance did Zynex report for 2023?
Are Zynex's products FDA approved?
What new products has Zynex recently introduced?
Where can I find more information about Zynex Inc?
